Health

Understanding Bipolar Disorder in Women

March 11, 2026|12:00 PM Irish time|Past event

With a 112% surge in first-onset bipolar disorder during perimenopause, millions of women face heightened risks of misdiagnosis, rapid cycling, and suicide without timely intervention.

Key takeaways

  • Recent studies reveal hormonal shifts in perimenopause and postpartum periods are driving increased bipolar diagnoses in women, outpacing men in bipolar II prevalence.
  • Women with bipolar disorder endure more depressive episodes, comorbidities like anxiety and metabolic issues, leading to greater disability and healthcare burdens.
  • Global projections to 2041 indicate a persistent high burden of bipolar disorder among reproductive-age women, exacerbated by barriers like treatment costs and waiting times.

Women's Bipolar Burden

Bipolar disorder affects 37 million people worldwide, with women more frequently diagnosed despite equal overall prevalence. This disparity stems from gender-specific manifestations, where women often experience bipolar II, characterized by predominant depression rather than severe mania. Recent genomic studies, including the largest-ever analysis in 2025, have illuminated genetic factors, doubling known associations and highlighting biological underpinnings.

Hormonal fluctuations play a pivotal role. A 2024 study found a 112% increase in first-onset bipolar symptoms during perimenopause, linking estrogen declines to mood instability. Postpartum periods also heighten vulnerability, with barriers to perinatal management including patient denial, provider gaps, and systemic delays. In 2025, the World Health Organization noted low treatment coverage, with misdiagnosis common—women often labeled with major depression, delaying proper care by up to 11 years.

Real-world impacts are profound. Women report more rapid cycling—four or more episodes yearly—and mixed states, correlating with higher suicide attempts. Comorbidities compound this: 29.6% of women exhibit rapid cycling versus 16.6% of men, alongside elevated anxiety, eating disorders, and physical pain. Economically, high socio-demographic index regions bear the heaviest standardized rates, with projections showing slight declines in incidence but sustained prevalence and disability-adjusted life years through 2041.

Non-obvious tensions arise in treatment. Lithium monitoring is essential, but valproate is contraindicated for pregnant or breastfeeding women due to risks. Substance abuse is lower in women, yet metabolic disorders and cancer rates are higher, influenced by medications. Advocacy groups like BD² awarded $18 million in grants in October 2025 to advance biology research, emphasizing women's health amid historical exclusions. Ireland's Aware, marking 40 years in 2026, released a survey revealing improved attitudes but persistent access barriers, underscoring urgency in a post-pandemic era of rising mental health needs.

We use cookies to measure site usage. Privacy Policy